Valorisation of Insect Farming By-Products into Chitosan: Chemical Characterisation and Bioactivity for Veterinary Use
- 1Egas Moniz Center for Interdisciplinary Research (CiiEM), Egas Moniz School of Health & Science, 2829-511 Caparica, Portugal
- 2Thunder Foods, 2005-332 Santarém, Portugal
Abstract
Insect-farming by-products provide an alternative source for chitin and chitosan production, adding value to existing protein-production systems. This narrative review examines extraction, physicochemical characterisation and bioactivity from documented by-products of Hermetia illucens and Tenebrio molitor. Veterinary applications are discussed separately, drawing on studies using chitosan of other or unspecified origins to identify potential uses and the evidence needed for insect-derived materials. Exuviae, empty puparia and documented adult residues are distinguished from whole-insect materials used as methodological comparators. Chemical, enzyme-assisted and intensified processes produce materials with different degrees of deacetylation, molecular weights, residual components and recoveries; yields relative to biomass are distinguished from conversion yields relative to isolated chitin. Direct insect-derived evidence consisted mainly of in vitro antimicrobial, antioxidant, epithelial-response, haemocompatibility and degradation assays, with limited preclinical haemostatic testing. No veterinary clinical or field study using a defined insect-derived chitosan product was identified. Studies of wound management, tissue repair, delivery systems and dietary supplementation showed formulation-, dose- and species-dependent responses, without establishing equivalence between chitosan sources. Veterinary translation requires traceable sources, reproducible processing, validated characterisation, contaminant control and product-specific safety and efficacy studies. Environmental and economic benefits also require comparative assessment. Insect-derived chitosan therefore warrants further investigation as a veterinary biomaterial, with suitability demonstrated for each preparation and application.
Related
- Natural Products against Human and Veterinary Trichomonads: From In Vitro Activity to Future Therapeutic Perspectives
- Accelerating the Discovery of Marine Natural Products with Antimicrobial activity via Bioactivity-Driven Molecular Networking
- La géodiversité en région Île-de-France : inventaire, protection et valorisation
- Valorisation of bread surplus as ingredients: impact of milling on bread powders properties
- Coupled enzyme discovery, evolution and synthetic yeast chassis adaptation for microbial biopolymer valorisation
BibTeX
@article{ligeiro2026valorisation,
title = {{Valorisation of Insect Farming By-Products into Chitosan: Chemical Characterisation and Bioactivity for Veterinary Use}},
author = {Carolina Ligeiro and Daniel Murta and Luísa Lima Gonçalves},
journal = {Molecules},
year = {2026},
month = oct,
doi = {10.3390/molecules31203782},
url = {https://www.mdpi.com/1420-3049/31/20/3782},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Valorisation of Insect Farming By-Products into Chitosan: Chemical Characterisation and Bioactivity for Veterinary Use
AU - Carolina Ligeiro
AU - Daniel Murta
AU - Luísa Lima Gonçalves
PY - 2026
DA - 2026/10/01
JO - Molecules
DO - 10.3390/molecules31203782
UR - https://www.mdpi.com/1420-3049/31/20/3782
AB - Insect-farming by-products provide an alternative source for chitin and chitosan production, adding value to existing protein-production systems. This narrative review examines extraction, physicochemical characterisation and bioactivity from documented by-products of Hermetia illucens and Tenebrio molitor. Veterinary applications are discussed separately, drawing on studies using chitosan of other or unspecified origins to identify potential uses and the evidence needed for insect-derived materials. Exuviae, empty puparia and documented adult residues are distinguished from whole-insect materials used as methodological comparators. Chemical, enzyme-assisted and intensified processes produce materials with different degrees of deacetylation, molecular weights, residual components and recoveries; yields relative to biomass are distinguished from conversion yields relative to isolated chitin. Direct insect-derived evidence consisted mainly of in vitro antimicrobial, antioxidant, epithelial-response, haemocompatibility and degradation assays, with limited preclinical haemostatic testing. No veterinary clinical or field study using a defined insect-derived chitosan product was identified. Studies of wound management, tissue repair, delivery systems and dietary supplementation showed formulation-, dose- and species-dependent responses, without establishing equivalence between chitosan sources. Veterinary translation requires traceable sources, reproducible processing, validated characterisation, contaminant control and product-specific safety and efficacy studies. Environmental and economic benefits also require comparative assessment. Insect-derived chitosan therefore warrants further investigation as a veterinary biomaterial, with suitability demonstrated for each preparation and application.
SN - 1420-3049
ER -